Adage Capital Partners Portfolio holdings
AUM
$59.3B
1-Year Return
26.26%
This Quarter Return
+5.25%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$57.2B
AUM Growth
+$551M
(+0.97%)
Cap. Flow
-$296M
Cap. Flow
% of AUM
-0.52%
Top 10 Holdings %
Top 10 Hldgs %
31.76%
Holding
1,007
New
143
Increased
295
Reduced
385
Closed
137
Top Buys
| 1 |
ConocoPhillips
COP
|
+$230M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$185M |
| 3 |
WESCO International
WCC
|
+$171M |
| 4 |
Gilead Sciences
GILD
|
+$158M |
| 5 |
Delta Air Lines
DAL
|
+$148M |
Top Sells
| 1 |
MRO
Marathon Oil Corporation
MRO
|
+$221M |
| 2 |
3M
MMM
|
+$154M |
| 3 |
Marsh & McLennan
MMC
|
+$115M |
| 4 |
Johnson & Johnson
JNJ
|
+$99M |
| 5 |
Novo Nordisk
NVO
|
+$94.6M |
Sector Composition
| 1 | Technology | 29.09% |
| 2 | Healthcare | 13.87% |
| 3 | Financials | 11.48% |
| 4 | Consumer Discretionary | 10.65% |
| 5 | Industrials | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
ProQR Therapeutics
PRQR
$237M
| $25.4M | 0.04% |
9,602,280
+5,976,813
| +165% | +$15.8M |
|
377
Emerson Electric
EMR
$75.2B
| $25.4M | 0.04% |
205,261
-629,135
| -75% | -$78M |
|
378
Everest Group
EG
$14.3B
| $25.4M | 0.04% |
70,181
+39,400
| +128% | +$14.3M |
|
379
Kraft Heinz
KHC
$31.5B
| $25.3M | 0.04% |
824,732
+90,800
| +12% | +$2.79M |
|
380
Marvell Technology
MRVL
$57.8B
| $25.2M | 0.04% |
228,328
-274,500
| -55% | -$30.3M |
|
381
HP
HPQ
$26.5B
| $25M | 0.04% |
765,436
-57,000
| -7% | -$1.86M |
|
382
Benitec Biopharma
BNTC
$350M
| $24.9M | 0.04% |
1,972,524
+1,131,129
| +134% | +$14.3M |
|
383
Crescent Energy
CRGY
$2.22B
| $24.8M | 0.04% |
1,700,000
+1,675,000
| +6,700% | +$24.5M |
|
384
Tyler Technologies
TYL
$23.6B
| $24.5M | 0.04% |
42,500
+7,300
| +21% | +$4.21M |
|
385
Global Payments
GPN
$20.6B
| $24.5M | 0.04% |
218,260
-21,600
| -9% | -$2.42M |
|
386
Paychex
PAYX
$47.9B
| $24.4M | 0.04% |
174,246
-77,900
| -31% | -$10.9M |
|
387
International Flavors & Fragrances
IFF
$16.5B
| $24.4M | 0.04% |
288,900
+47,900
| +20% | +$4.05M |
|
388
Equifax
EFX
$30.3B
| $24.4M | 0.04% |
95,800
-20,800
| -18% | -$5.3M |
|
|
GEAR
389
DELISTED
Revelyst, Inc.
GEAR
| $24.3M | 0.04% |
+1,265,474
| New | +$24.3M |
|
390
Raymond James Financial
RJF
$33.2B
| $24.3M | 0.04% |
156,400
-18,350
| -11% | -$2.85M |
|
391
Quanta Services
PWR
$58.1B
| $24.2M | 0.04% |
76,591
-62,300
| -45% | -$19.7M |
|
392
Carnival Corp
CCL
$42.5B
| $24.2M | 0.04% |
970,500
+798,800
| +465% | +$19.9M |
|
393
Merit Medical Systems
MMSI
$5.26B
| $24.2M | 0.04% |
250,000
| – | – |
|
394
Mettler-Toledo International
MTD
$25.8B
| $24.2M | 0.04% |
19,757
-29,200
| -60% | -$35.7M |
|
395
Renasant Corp
RNST
$3.67B
| $24.1M | 0.04% |
672,729
+117,385
| +21% | +$4.2M |
|
396
Spyre Therapeutics
SYRE
$977M
| $24M | 0.04% |
1,030,000
-25,000
| -2% | -$582K |
|
397
Aclaris Therapeutics
ACRS
$221M
| $23.9M | 0.04% |
+9,627,304
| New | +$23.9M |
|
398
Penumbra
PEN
$10.6B
| $23.9M | 0.04% |
+100,495
| New | +$23.9M |
|
399
Alcon
ALC
$38.5B
| $23.9M | 0.04% |
+281,020
| New | +$23.9M |
|
400
F5
FFIV
$18.8B
| $23.8M | 0.04% |
94,740
-50,600
| -35% | -$12.7M |
|